Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01939678

Enrollment

Registered

2013-09-11

Start date

2013-09-30

Completion date

2019-09-30

Last updated

2019-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis

Brief summary

The purpose of this study is to investigate whether mutations in genes coding for Na/Pi-cotransporters are associated with aortic valve calcification. A patient population with premature aortic valve calcification treated with aortic valve replacement will be screened for mutations in these specific genes. Furthermore, aortic valve tissue received from the operations, will be examined for the presence of Na/Pi-cotransporters, and for molecular characterization of the transporters.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 65 Years

Healthy volunteers

Inclusion criteria

* Patients with aortic valve calcification that will be treated with an aortic valve replacement. * Age ≤ 65 years. * Signed and dated informed consent.

Exclusion criteria

* Inability to provide informed consent * Earlier radiation therapy of the thorax * Severe renal disease (patients in treatment with dialysis)

Design outcomes

Primary

Measure	Time frame	Description
Mutations in sodium-phosphate cotransporters in patients with calcific aortic valve disease	At the time of aortic valve replacement	Mutations in genes coding for Na/Pi-cotransporters

Countries

Sweden

Outcome results